Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

83.94USD
10:14am EST
Change (% chg)

$0.61 (+0.73%)
Prev Close
$83.33
Open
$83.73
Day's High
$84.25
Day's Low
$83.37
Volume
60,976
Avg. Vol
648,188
52-wk High
$96.28
52-wk Low
$57.01

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $24,161.52
Shares Outstanding(Mil.): 210.65
Dividend: --
Yield (%): --

Financials

  INCY.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -0.78 -- --
ROI: -11.99 8.92 14.45
ROE: -23.24 10.08 15.96

Incyte loses trade-secret case against Flexus over cancer drug

A Delaware state court jury has rejected pharmaceutical company Incyte Corp's claims that rival Flexus Biosciences Inc was unjustly enriched by stealing cancer drug research trade secrets from it before Bristol-Myers Squibb Co acquired Flexus in 2015.

Nov 08 2018

BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results

* PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC

Oct 19 2018

Earnings vs. Estimates